AUSCUSTOM PHARMA SDN BHD achieves Entry Point Project (EPP) status in Malaysia
January 4, 2016
Singapore, 4 January 2016 – AUSCUSTOM PHARMA SDN BHD is awarded EPP status from the Malaysian Ministry of Health to operate the largest GMP compounding pharmacy facility in SE ASIA. The project is the first (and only to date) GMP Compound Pharmacy project in Malaysia. The National Pharmaceutical Regulatory Agency views this facility to be the benchmark standard for the entire Compound Pharmaceutical industry in Malaysian.
The Economic Transformation Programme (ETP) in Malaysia was launched with 131 Entry Point Projects (EPPs). The National Key Economic Areas (NKEAs) are the engines of growth, while the Entry Point Projects are the spark plugs that will fire up these engines, to a new level of performance. They are called Entry Point Projects because these projects kick start the programme and they are not finite. These are high impact projects, matched with specific ideas and actions, to spur the growth of the NKEAs. Some involve large infrastructure investments while others have a more direct effect on the output of their sectors and on the life of Malaysians. These are all focussed on actions and not mere concepts.